Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

The PGIM Jennison Health Sciences Fund lost value, underperforming its benchmark Index during the Q1 of 2025. Click here to ...

Eli Lilly has delivered a jaw-dropping 635% stock price increase from 2020 to 2024, driven by high hopes and heavyweight drug ...